Novel Drug Shrinks 73% of HER2-Mutant Lung Cancers

MedPage Today) — An investigational antibody-drug conjugate proved active and safe for patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC), a phase II trial from China showed.
Of 94 patients with locally advanced…